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Objective: In this study, we report an experience of 59 natural-cycle IVF combined with in vitro oocyte
maturation (IVF/M) cycles in patients with PCOS requiring IVF recruited based on limitations to afford a
conventional IVF treatment in a 9-years period. Results of IVF/M were compared with 164 cycles of IVF in
PCOS patients.
Material and methods: In IVF/M cycles only hCG priming was used before oocyte recovery, with in vitro
maturation of immature oocytes in a commercial medium. In conventional IVF group, recombinant FSH
(rFSH) and GnRH agonist/antagonist for ovarian stimulation were used. In both groups, fertilization was
achieved by intracytoplasmic sperm injection (ICSI) of mature oocytes and fresh embryos transferred at
day 2 or day 3.
Results: In all IVF/M cycles oocytes and transferable quality embryos were obtained, only in 6 IVF/M
cycles mature oocytes were obtained at oocyte capture day. Clinical pregnancy rate per cycle was 39.0%
vs 53.6% (p ¼ 0.0682) and delivery rate per cycle was 30.5% vs 42.6% (p ¼ 0.1209) in IVF/M and con-
ventional IVF respectively. Patients with ovarian hyperstimulation syndrome (OHSS) were 0% in IVF/M vs
6.7% in conventional IVF (p ¼ 0.0399).
Conclusion: Our experience in a private clinic in Mexico suggests that IVF/M can be a useful initial
strategy to treat PCOS patients requiring IVF with comparable delivery rates to conventional IVF and a
decreased risk of ovary hyperstimulation. IVF/M may be indicated to patients with limited resources
paying without insurance for their infertility treatment.
© 2019 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In vitro maturation (IVM) is an assisted reproduction technique
(ART) with an interesting evolution. Since the report of the ﬁrst
pregnancy in the 900s [1], IVM was proposed as a technique with a
lot of potential and gained popularity in infertility clinics. This initial
enthusiasm has been lost because of reduced pregnancy rates of
IVMwhen is compared to routine IVF [2]. Currently, few groups are
active in clinical and basic research. Clinical trials are lacking and
there are many questions in relation to laboratory procedures: howaseo del Moral y Av. Guana-
xico. Fax: þ52 477 779 0836.
z-Gutierrez).
Gynecology. Publishing services bto optimize maturation rate and embryo development? which
culture media to use? Also, we still have clinical uncertainties such
as the importance of priming with FSH or hCG, the effect of lack of
experience during immature oocyte pick up, the feasibility of
blastocyst culture and the precise clinical indications for IVM [3].
A review of literature conﬁrmed that IVM is inferior to conven-
tional stimulation in relation to pregnancy and take-home baby
rates [3]. This probably supports the apparent “abandon” of IVM
during the last years and the resistance of IVF clinics worldwide to
include IVM in their routine procedures. However, the movement of
“mild approaches” and patient friendly-IVF are considering IVM as
useful tool [4]. IVM can offer higher pregnancy rates than natural
cycles and both natural cycles combinedwith IVM or IVM practically
eliminate the risk of ovarian hyperstimulation syndrome (OHSS).y Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Basal characteristics of patients enrolled.
IVM/F IVF Two tailed p-value
Age (years) 27.9 ± 3.6
Range (19e40)
32.07 ± 4.09
Range (20e43)
0.5609
BMI (Kg/m2) 27.3 ± 4.6 26.3 ± 5.9 0.2398
Years of infertility 4.5 ± 3.17 5.2 ± 3.7 0.1977
Primary infertility 81.4% (48/59) 81.7% (134/164) 1.0000
ART indications
Tubal factor 32.2% (19) 29.3% (48) 0.7410
Male factor 28.8% (17) 31.7% (52) 0.7442
IUI failure 25.4% (15) 28% (46) 0.7368
Unexplained 13.5% (8) 11% (18) 0.6378
AFC 19.3 ± 4.6 17.5 ± 9.5 0.1641
FSH (IU/mL) 6.2 ± 1.8 6.6 ± 8.0 0.7042
LH (IU/mL) 8.30 ± 5.1 7.8 ± 3.8 0.4316
E2 (pg/mL) 39.7 ± 13.5 43.7 ± 29.4 0.3153
Testosterone (ng/dL) 0.66 ± 1.2 0.62 ± 1.2 0.8264
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is the main limitation for access to ART in countries where IVF is not
covered by health insurance or by the government [4].
In relation to safety, apparently IVM does not generate an
increased risk of malformations or chromosomal abnormalities [3].
Currentlymore than 5000 births are estimated from IVMworldwide
[4]. A review of 1421 babies born by IVM indicated no major risks,
reassuring in relation to safety and clinical potential of IVM [5].
In this report, we describe our clinical experience and obstet-
rical outcome of IVF/M cycles versus routine IVF offered to PCOS
patients requiring IVF in a private infertility clinic in Mexico.
Material and methods
Patients
We began to offer IVM as routine procedure in 2007. IVM is
routinely offered to all patients in our center with an antral follicle
count (AFC) > 15 who requires IVF and cannot afford it. The local
review board approved the procedure and present report. All
couples provided informed consent for the procedures. Consecutive
IVF/M cycles to PCOS patients requiring IVF because of several
indications without enough economic resources to perform IVF
from June 2007 to December 2016 were included. For compare the
results 164 cycles of conventional IVF of patients with PCOS treated
during the same period were included.
All patients had a full infertility workup, including semen
analysis, basal pelvic ultrasound, ovarian hormones, hystero-
salpingography, hysteroscopy and serological test for HIV, hepati-
tis B and hepatitis C. The diagnosis of PCOS was established ac-
cording to the revised Rotterdam ESHRE/ASRM criteria [6].
Ovary stimulation for IVF cycles
Patients in IVF groupwere stimulated using up to 150 U rFSH per
day (Gonal-F, Serono) and GnRH antagonist (cetrorelix acetate)
0.25 mg per day (Cetrotide, Serono) or 0.1 mg of triptoreline
(Gonapeptyl daily, Ferring Pharmaceuticals) with triggering when a
follicle reached 18 mm using 5000 hCG (Choragon, Ferring Phar-
maceuticals Mexico) or 250 mg of rhCG (Ovidrel, Merck Serono).
In-vitro maturation
A transvaginal ultrasound scan was performed to all patients
enrolled on day 2 or 3 of their menstrual cycle (natural or induced)
to asses AFC. The number of antral follicles (>2 mm in diameter) in
both ovaries was recorded. No FSH priming was used. On day 7
another trans-vaginal ultrasound scanwas performed, then daily or
on alternate days thereafter as required. When at least one follicle
reached 12 mm and/or endometrial thickness was 7 mm patients
received a single IM injection of 10,000 hCG (Choragon, Ferring
Pharmaceuticals Mexico) or 250 mg of rhCG (Ovidrel, Merck
Serono). 37 h after hCG injection oocyte retrieval was performed
under patient IV sedation using a 17G x 20 single lumen needle
(Kitazato Oocyte Pickup Needle) and vacuum pressure of 50mmHg.
Aspirated ﬂuid was collected in 10 mL round tubes containing a
0.9% NaCl solution supplemented with 2U/mL of sodium heparin.
Retrieved cumulus oocytes complexes were evaluated with an
inverted microscope using the sliding method [7]. If no germinal
vesicle (GV)was observed in the oocyte cytoplasm, cumulus cellswere
removed using hyaluronidase (InVitroCare) and mechanical pipetting
for reassessment of maturity after denuding. When mature (meta-
phase II) oocytes were found on the collection day they were insem-
inated by ICSI. Immature oocytes (GV or metaphase I oocytes) were
cultured in IVMmedia (SAGE) supplemented with 0.75 IU/mL of rFSHand 0.75 IU/mL of rLH. After 24 h of culture oocytes were examined, if
oocytes remained at GV or MI stage those were cultured in the same
medium and re-evaluated 24 h later. Oocytes in metaphase II were
injected with spermatozoa obtained by gradient centrifugation (Pure
Sperm) combined with a swim-up procedure. Injected oocytes were
transferred to Global medium (LifeGlobal) covered with parafﬁn oil
(LifeGlobal) and incubated at 37 C in 6.5% CO2. After 18 h, fertilization
was evaluated by the presence of 2 pronuclei and 2 polar bodies.
Embryos were culture in 20 ml droplets of Global medium at 37 C in
6.5% CO2, according to standard procedures and embryo transfers
performed on day 2 or 3 of embryo culture.
Endometrial preparation
Patients started oral estradiol valerate (EV) (Primogyn, Bayer
Mexico) at the day of oocyte retrieval. Dosage was individually
calculated depending upon endometrial thickness: < 7 mm,
patients received 10 mg daily and if it was 7 mm a 6 mg dose was
administered. Luteal support was provided with 50 mg/day of IM
progesterone (Progesterone injection USP, Hikma Farmaceutica,
Portugal) starting on the day of ICSI and continued along with EV,
until 12 weeks of gestation, if patient was pregnant. Embryo
transfer was performed using an Ultrasoft Frydman catheter set
(Laboratorie CCD, France) with echogenic guide.
Statistical analysis
Statistical analysis was performed in GraphPad Prism 5 soft-
ware. Proportions were evaluated by Exact Fisher test with two
tailed p-values. Continuous variables are presented in tables as
mean ± standard deviation and t-test were used for hypothesis
testing using two tailed p-values.
Results
A total of 59 patients with PCO requiring IVF were enrolled to
perform IVM as ART. All of them had a PCOS diagnosis and accepted
to perform an IVF/M because reduction in cost of the procedure.
This cohort was compared with 164 PCOS patients in conventional
IVF cycles. Basal characteristics of both groups are show in Table 1,
no signiﬁcant differences were found on both groups. Indications
for IVF in IVM/F vs IVF groupswere tubal infertility (32.2% vs 29.3%),
male factor (28.8% vs 31.7%), failure to conceive after 3 cycles of
intrauterine insemination (25.4% vs 28%) and unexplained infer-
tility (13.5% vs 11%) (Table 1).
We obtained amedia of 16.9± 9.4 oocytes vs 18± 9.8 (p¼ 0.4557)
per ovum pick up in IVF/M vs IVF. Only in six IVF/M patients (10%) a
C. Gonzalez-Ortega et al. / Taiwanese Journal of Obstetrics & Gynecology 58 (2019) 192e195194mature oocytewas found in IVF/Mon the day of retrieval. If so, it was
decumulated and injected by ICSI the same day of the recovery,
embryos from mature oocytes were transferred with the other
embryos resulted from IVM for a mean number of embryos 2.8 ± 0.8
vs 2.43 ± 0.6 in IVF (p ¼ 0.3700) (Table 2). Findings on embryo
quality, embryos transferred and results in terms of pregnancy, im-
plantation abortion and delivery rate are described in Table 2. Em-
bryo quality in IVF/M group was lower, with a decreased cleavage
rate 84.6% ± 4.9 vs 90.5% ± 5.0 (p ¼ 0.0001) and less good quality
embryos 43.3% vs 63.4% in IVF (p¼ 0.0001) assessed bymorphology
score. The number of good quality embryos per cyclewas 3.1 ± 2.5 in
IVF/M vs 6.1 ± 2.3 in IVF group (p ¼ 0.0001).
Only two patients in IVM/M group were not transferred
(Table 2) because of deﬁcient endometrial growth, but they
generated transferable good quality embryos which were vitriﬁed.
As it is expected, endometrial thickness is signiﬁcantly decreased in
IVF/M group (Table 2). So far, no pregnancies have been obtained
with frozen-thawed embryo transfer on IVF/M group. In the
fresh embryo transfer, pregnancy rates per cycle were 39% vs
53.6% (p ¼ 0.0682). Delivery rate per cycle was 30.5% vs 44.8%
(p ¼ 0.1209) in IVF/M vs IVF. 23 pregnancies from IVF/M cycles (6
doubles and 17 singletons) were obtained leading to 5 miscarriages
and 18 deliveries of 24 healthy babies. No major or minor malfor-
mations were found in both groups. Until now, six frozen embryos
transfers have not produced pregnancies. We hypothesize, this is
related with the lower quality of embryos in IVF/M group (Table 2).
Discussion
In Mexico and other Latin-American countries, experience with
IVM is restricted; an initial attempt in Mexico was reported using
only hCG priming [8]. Our center previously reported a case of IVM
in a normoovulatory female for treatment of azoospermia in her
partner [9]. The limited availability of IVM can be related with
hurdles to establish a new ART in private settings in low or medium
income countries because the cost of treatment is carried
completely by the patients.
In our center, IVF/M is offered for all patients with PCOS
requiring IVF when they cannot afford the cost of routine IVF. The
cost of conventional IVF is about 4000 dollars and the cost of IVF/MTable 2
Clinical, laboratory and obstetrical outcomes of IVF/M cycles vs conventional IVF.
IVF/M
Number of cycles 59
Number of cycles with ET (%) 98.3% (57)
Patients with OHSS 0% (0/59)
OCC recovered 16.9 ± 9.4
Cycles with MII oocyte at retrieval 10.1% (6)
Number of MII oocytes At 24 h
9.4 ± 4.5
Maturation rate at 24 h (%) 63.2 ± 6.8
Fertilization rate (%) 87.7 ± 4.68
Cleavage rate (%) 84.6 ± 4.9
Percentage of good quality embryos 43.3% (183/422)
Number of good quality embryos per cycle 3.1 ± 2.5 (183)
Number of transferred embryos 2.8 ± 0.8 (160)
Endometrial thickness (mm) 7.6 ± 1.9
Clinical pregnancy rate/cycle 39.0% (23/59)
Clinical pregnancy rate/ET 40.3% (23/57)
Implantation rate 18.1% (29/160)
Abortion rate 21.7% (5/23)
Multiple pregnancy rate 26.1% (6/23)
Delivery rate per cycle 30.5% (18/59)
Delivery rate per transfer 31.6% (18/57)
Newborns 24
Gestational weeks 36.2 ± 2.2
Weight 2620 ± 470 gis 2000 dollars. Using IVM/M is an innovative approach because
IVM is normally only considerer after multiple IVF failures or OHSS
[2e4]. Our medium-term goal is to use IVF/M as ﬁrst line treatment
for PCOS. We always provide counseling about the lower success
rates compared to conventional stimulation IVF reported in litera-
ture but highlighting the advantages such as decreased risk of
OHSS and the important reduction in the cost of treatment.
It is not clear which are the clinical indications that may provide
an adequate pregnancy rate for IVF/M or IVM. The most important
indications are PCOS patients, especially patients with high risk of
OHSS and in cancer patients with an oncofertility indications, such
as estrogen sensitive malignant tumors and patients requiring
rapid oocyte retrieval before gonadotoxic treatment [2,4]. However,
IVM was proposed as a “mild and friendly” ART that can be useful
despite its lower rates [4]. Emergency fertility preservation is
gaining popularity because cancer treatment in young women is
more frequent, this is an important indication to have an active
program of IVM [2]. Our clinic is also moving to this approach for
fertility preservation when ovary stimulation is not possible.
Our results are comparable to IVF in Latin America; clinical
pregnancy rate per cycle is 31% for ICSI cycles according 2014 report
of Latin-American registry of assisted reproduction [10]. Therefore,
our results of 39% clinical pregnancy rate with IVF/M are similar to
the overall clinical pregnancy rate of ICSI in Latin America. Up to
now, IVM is considered as an experimental procedure according the
ASRM [2], because the best available evidence indicates lower
pregnancy rates. This fact limits its application in US and other Latin
American countries.
In the other hand, the latest ESHRE report of assisted repro-
duction in Europe describing the cycles practiced in 2013 indicates
that ten countries are performing IVM, mainly in France (48% of the
cycles) and Poland. In total, there were 247 cycles that represents a
decrease compared to previous years (421 in 2012, 511 in 2011);
IVM corresponds only to 0.3% of the 688,271 cycles performed in
Europe in 2013 [11]. From the 247 aspirations recorded, 137
transfers were performed resulting in 35 pregnancies and 25 de-
liveries. (25.5% pregnancy rate and 18% delivery rate per transfer).
Our pregnancy rates and delivery rates are higher than Europe. This
can be related with the selection of patients, differences in drugs
used or the good prognosis of patients recruited in our cohort.IVF Two tailed p-value
164
92.3% (156) 1.0000
6.7% (11/164) 0.0399
18.0 ± 9.8 0.4557
NA
At decumulation
12.4 ± 6.0
0.0006
NA
86.7% ± 5.67 0.2262
90.5% ± 5.0 0.0001
63.4% (1002/1580) 0.0001
6.1 ± 2.3 (1002) 0.0001
2.43 ± 0.6 (381) 0.3700
8.3 ± 2.0 0.0204
53.6% (88/164) 0.0682
56.4% (88/156) 0.0444
31.2% (119/381) 0.0021
20.4% (18/88) 0.5590
29.5% (26/88) 0.8026
42.6% (70/164) 0.1209
44.8% (70/156) 0.0864
96
37.1 ± 2.3 0.864
2826 ± 652 g 0.1486
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based in the type of hormonal priming [12]. While in the past IVM
was considered even if FSH or hCG primingwere given, nowadays it
is considered as natural IVF/M when hormonal priming is used.
This will affect how IVM data are collected in the future. Contro-
versy exists in relation to a negative effect of hCG and a Cochrane
review proposed a harmful effect [13]. More research is urgently
needed to optimize the protocols and standardize terminology [4].
An interesting ﬁnding in this study was the relative high (26.1%)
multiple pregnancy rate, no signiﬁcantly different (p ¼ 0.8026)
from the 29.5% of conventional IVF. This is a clear reminder that
despite IVM offers protection from OHSS in PCOS patients (Table 2),
IVM is associated to an important risk of multiple pregnancies. This
risk should be appropriately counseled and potentially avoided by
transferring less embryos or moving to single embryo transfer.
Elective single blastocyst transfer in IVM cycles with similar results
of day 3 transfer has been reported [14]. Further research of IVM in
good prognosis PCOS patients, like our cohort, is needed to clarify
the optimal number of embryos to transfer and if blastocyst culture
can be combined with IVM to effectively increase delivery rates.
Despite the limitations of small sample size, lack of randomi-
zation and patients coming from a single center, our results suggest
that IVF/M can be used in patients with PCOS requiring IVF
with satisfactory delivery rates. IVF/M provides a budget friendly
approach for patients covering out of the pocket the cost of infer-
tility treatment. Further randomized studies are required to opti-
mize the best IVM protocols, along with a detailed health
economics study comparing IVF/M and IVF in PCOS patients.
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